Insulet Slides After Q1 Beat as Omnipod 5 Class I Recall Overhang Persists
PODD•Insulet shares fell as investors digested first-quarter 2026 results released May 6, 2026, despite an earnings and revenue beat. The decline is being amplified by ongoing scrutiny of a Class I recall involving certain Omnipod 5 pod lots tied to potential insulin under-delivery risk.
1) What’s moving the stock
Insulet (PODD) is down about 3.66% on Wednesday, May 6, 2026, following the company’s first-quarter 2026 results and investor call. The move comes even as quarterly results topped consensus expectations, signaling that near-term positioning and risk concerns are outweighing the headline beat. (investor.insulet.com)
2) Earnings beat, but the tape stays heavy
In the first quarter, Insulet reported revenue of $761.7 million and diluted EPS of $1.42, both ahead of published expectations in the market. The stock reaction suggests investors are focusing less on the quarter’s upside and more on forward risk factors and sentiment after an extended drawdown toward recent lows. ()
